Status:
UNKNOWN
Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia
Lead Sponsor:
Mohammed Abd El Mawgoud Amer
Conditions:
Androgenic Alopecia
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Androgenetic alopecia (AGA) is hair loss with specific clinical pattern, It Is characterized by follicular miniaturization, which occurs due to systemic androgens and genetic factors. Prevalence diffe...
Detailed Description
Androgenetic alopecia may affect self-esteem and quality of life in several affected individuals. There are two FDA-approved drugs for pattern baldness: topical minoxidil and finasteride, both of whic...
Eligibility Criteria
Inclusion
- Subjects clinically and dermoscopic diagnosed with AGA.
- Age ranges from 18 to 45 years old.
- Males
- Willingness to provide pictures and follow-up studies.
Exclusion
- Patients who received any topical or systemic treatment for AGA during the last 6 months,
- Patients who had other types of alopecia such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia.
- Patients with anemia, thyroid disease, and vitamin D deficiency,
- Any autoimmune disease or chronic debilitating disease (chronic renal failure, congestive heart failure, hepatic patients, cancer patients).
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05369481
Start Date
March 1 2022
End Date
September 1 2022
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AL-Azhar University Hospital
Cairo, Egypt, 11865